atrasentan has been researched along with Disease Exacerbation in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (65.22) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Andreucci, M; De Nicola, L; Garofalo, C; Minutolo, R; Provenzano, M; Serra, R | 1 |
| Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Dey, J; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M | 1 |
| Nangaku, M | 1 |
| Andress, D; Becker, K; Johnson, AC; Zager, RA | 1 |
| Agarwal, N; Carducci, MA; Cote, RJ; Datar, RH; Ely, B; Fink, LM; Garzotto, M; Goldkorn, A; Higano, CS; Hussain, M; Lara, P; Mack, PC; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, P; Van Veldhuizen, PJ; Vogelzang, NJ; Xu, T | 1 |
| Batu Demir, D; Cooper, ME | 1 |
| Carducci, M; Chin, JL; Love, W; Nelson, JB; Qian, J; Saad, F; Schulman, CC; Sleep, DJ; Steinberg, J | 1 |
| Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Kujal, P; Vaneckova, I; Vernerová, Z | 1 |
| Andress, DL; Brennan, J; Coll, B; Kohan, DE; Molitch, M; Pritchett, Y | 1 |
| Gulati, R; Lennon, R; Lerman, A; Lerman, LO; Mario, G; Reriani, M; Rihal, C; Tilford, JM; Yoon, MH | 1 |
| Carr, RA; Groenewegen, G; Humerickhouse, RA; Isaacson, JD; Janus, TJ; Leahy, TW; Voest, E; Zonnenberg, BA | 1 |
| Carducci, MA; Lassiter, LK | 1 |
| Lee, D | 1 |
| Fisher, M | 1 |
| Nelson, JB | 2 |
| Carducci, M; Jimeno, A | 1 |
| Choueiri, TK; Garcia, JA; Thakkar, SG | 1 |
| Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR | 1 |
| Abrahamsson, PA; Carducci, MA; Dearnaley, DP; Isaacson, JD; Nelson, JB; North, SA; Saad, F; Schulman, CC; Sleep, DJ | 1 |
| van der Boon, J | 1 |
6 review(s) available for atrasentan and Disease Exacerbation
| Article | Year |
|---|---|
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease.
Topics: Animals; Atrasentan; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Proteinuria; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Renal Insufficiency, Chronic | 2021 |
New strategies to tackle diabetic kidney disease.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Pyrrolidines; Renal Artery; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Sympathectomy | 2016 |
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Bosentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Homozygote; Hypertension; Male; Podocytes; Pyrrolidines; Rats; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2009 |
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2003 |
Endothelin receptor antagonists.
Topics: Apoptosis; Atrasentan; Biomarkers, Tumor; Clinical Trials as Topic; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Treatment Outcome | 2005 |
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Topics: Apoptosis; Atrasentan; Bone Neoplasms; Clinical Trials as Topic; Disease Progression; Endothelins; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines | 2005 |
11 trial(s) available for atrasentan and Disease Exacerbation
| Article | Year |
|---|---|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Precision Medicine; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Severity of Illness Index | 2018 |
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Castration; Cell Count; Disease Progression; Docetaxel; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2014 |
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prognosis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome | 2008 |
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2008 |
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Topics: Aged; Albuminuria; Atrasentan; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Edema; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Hispanic or Latino; Humans; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis.
Topics: Adult; Atherosclerosis; Atrasentan; Disease Progression; Double-Blind Method; Early Diagnosis; Endothelin A Receptor Antagonists; Female; Follow-Up Studies; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Pyrrolidines; Receptor, Endothelin A; Time Factors | 2013 |
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Atrasentan; Carcinoma; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Time Factors | 2003 |
Clinical trials of atrasentan in hormone-refractory prostate cancer.
Topics: Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Neoplasm Metastasis; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Survival Analysis; Treatment Outcome | 2003 |
The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Atrasentan; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelin-1; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Risk Assessment; Treatment Outcome | 2002 |
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid | 2006 |
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines | 2007 |
6 other study(ies) available for atrasentan and Disease Exacerbation
| Article | Year |
|---|---|
Light of dawn in Melbourne: SONAR and CREDENCE.
Topics: Atrasentan; Australia; Canagliflozin; Clinical Trials as Topic; Congresses as Topic; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Kidney Failure, Chronic; Nephrology; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Topics: Animals; Atrasentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Kidney Failure, Chronic; Male; Mice; Mice, Inbred Strains; Oligopeptides; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Renal Insufficiency, Chronic; Reperfusion Injury; RNA, Messenger | 2013 |
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Male; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin | 2006 |
Atrasentan prolongs time to progression in prostate cancer patients.
Topics: Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Drug Administration Schedule; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Bone Resorption; Disease Progression; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
New drug slows prostate-cancer progression.
Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2002 |